Interleukin-2-interleukin receptor

Vigers, G.P.A., et al. Crystal structure of the type-1 interleukin-1 receptor complexed with interleukin-ip. Nature 386 190-194, 1997. 

Sergejeva S, Ivanov S, Lotvall J, Linden A Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation. Am J Respir Cell Mol Biol 2005 33 248-253. 96 Bush KA, Farmer KM, Walker JS, Kirkham BW Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgGl Fc fusion protein. Arthritis Rheum 2002 46 802-805. 

Garcia-Montero AC, Jara-Acevedo M. Teodosio C. et al KIT mutation in mast cells and other bone marrow hematopoietic cell hneages in systemic mast cell disorders a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006 108 2366-2372. Daley T, Metcalfe DD, Akin C Association of the Q576R polymorphism in the interleukin-4 receptor a chain with indolent mastocytosis limited to the skin. Blood 2001 98 880-882. 

Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, RothweU NJ, Tyrrell PJ. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005 76 1366-1372. 

The first etCCR application has been reported for a partially C— N-labeled phosphotyrosine peptide derived from interleukin-4 receptor ligated to STAT-6 [107] and subsequent studies involve nucleotide cofactors ligated to human recombinant deoxycytidine kinase [108] and epothilone A bound to tubulin [109]. Since etCCR usually involves isotope-labeling schemes for the ligand, its applicability is limited to specific molecular classes. 

The purported prophylactic use of Japanese herbal medicines to combat neuronal ageing has been related to their free-radical scavenging activity (Hiramatsu a al., 1992). Inhibition of the pro-inflammatory effects of cytokine interleukin-1 by recombinant endogenous interleukin-1 receptor antagonist in experimental rats is associated with alleviation of excitotoxic neuronal damage, an action which has also been related to the antiinflammatory effect of lipocortin 1 (Relton and Roth well, 1992). 

Relton, J.K. and Rothwell, N.J. (1992). Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damr e in the rat. Brain Res. Bull. 29, 243-246. 

IL-Ia. IL-1 8 Interleukin-la, -1(3 ILR Interleukin receptor IL-IR, IL-2R IL-3R - IL-6R Interleukin-1 - 6 receptors IL-lRa Interleukin-1 receptor antagonist... 

BUN, blood urea nitrogen Cl, calcineurin inhibitor CSA, cyclosporine IL-2RA, interleukin 2 receptor antagonist LFTs, liver function tests MMF, mycophenolate mofetil OKT-3, muronomab-CD3 RATG, rabbit antithymocyte immunoglobulin ... 

ATC, lymphocyte immune globulin, antithymoglobulin equine AZA, azathioprine BUN, blood urea nitrogen CSA, cyclosporine Cl, gastrointestinal IL-2RA, interleukin 2 receptor antagonist MMF, mycophenalate mofetil OKT-3, muronomonab-CD3 PRED, prednisone SCr, serum creatinine SRL, sirolimus TAC, tacrolimus WBC, white blood cell. 

Denileukin diftitox is a combination of the active sections of interleukin 2 and diphtheria toxin. It binds to high-affinity interleukin 2 receptors on the cancer cell (and other cells), and the toxin portion of the molecule inhibits protein synthesis to result in cell death. The pharmacokinetics of denileukin diftitox are best described by a two-compartment model, with an a half-life of 2 to 5 minutes and a terminal half-life of 70 to 80 minutes. Denileukin diftitox is used for the treatment of persistent or recurrent cutaneous T-cell lymphoma whose cells express the CD25 receptor. Side effects include vascular leak syndrome, fevers/chills, hypersensitivity reactions, hypotension, anorexia, diarrhea, and nausea and vomiting. 

Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science 1991 253 1278-1280. 

Clubb RT, Omichinski JG, Clore GM, Gronenbom AM. Mapping the binding surface of interleukin-8 complexes with an N-terminal fragment of the type 1 human interleukin-8 receptor. FEBS Lett 1994 338 93-7. 

Damaj BB, McColl SR, Neote K, et al. Identification of G-protein binding sites of the human interleukin-8 receptors by functional mapping of the intracellular loops. FASEB J 1996 10(12) 1426-1434. 

Dunstan C-AN, Salafranca MN, Adhikari S, Xia Y, Feng L, Harrison JK. Identification of two rat genes orthologous to the human interleukin-8 receptors. J Biol Chem 1996 271 32770-32776. 

Lloyd AR, Biragyn A, Johnston JA, et al. Granulocyte-colony stimulating factor and lipopolysaccharide regulate the expression of interleukin 8 receptors on polymorphonuclear leukocytes. J Biol Chem 1995 270 28188-28192. 

Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI. Characterization of two high affinity human interleukin-8 receptors. J Biol Chem 1992 267(23) 16283-16287. 

Moser B, Schumacher C, von Tschamer V, Clark-Lewis I, Baggiolini M. Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem 1991 266(16) 10666-10671. 

Morohashi H, Miyawaki T, Nomura H, et al. Expression of both types of human interleukin-8 receptors on mature neutrophils, monocytes, and natural killer cells. J Leukoc Biol 1995 57(1) 180-187. 

Stemmier S, Arinir U, Klein W, et al. Association of interleukin-8 receptor alpha polymorphisms with chronic obstructive pulmonary disease and asthma. Genes Immun 2005 6(3) 225-230. 

Shyamala V, Khoja H. Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells. Biochemistry 1998 37(45) 15918-15924. 

Ohlsson, K., Bjorn, P., Bergenfeldt, M Hageman, R., and Thompson, R.C., Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348,550-552 (1990). 

The interleukin-2 receptor (IL-2R) is important in that the cytokine IL-2, secreted by a subset of T-helper cells, enhances the proliferation of activated T and B cells and increases the cytolytic activity of natural killer (NK) cells and the secretion of IgG. 

DNA viruses modulate the host immune response, e.g., most likely the etiologic agent of Kaposfs sarcoma, KSHV (human herpes vims —8), has captured complement-binding proteins, three cytokines (two macrophage inflammatory proteins and interleukin 6), bcl-2, interferon regulatory factors, interleukin 8 receptor. Certain retroviruses... 

Reported applications of SASD involve modification of lipopolysaccharide (LPS) molecules and studying their interaction with albumin and an antibody directed against LPS (Wollenweber and Morrison, 1985), identification of the murine interleukin-3 receptor and an N-formyl peptide receptor (Sorenson et al., 1986), crosslinking of factor V and Va to iodinated peptides... 

Sorenson, P., Farber, N.M., and Krystal, G. (1986) Identification of the interleukin-3 receptor using an iodinatable, cleavable, photoreacdve cross-linking agent./. Biol. Chem. 261, 9094-9097. 

Tsudo, M., Kozak, R.W., Goldman, C.K., and Waldmann, T.A. (1987) Demonstration of a non-Tac peptide that binds interleukin 2 A potential participant in a multichain interleukin 2 receptor complex. Proc. Natl. Acad. Sci. USA 83, 9694-9698. 

Martin, M. and Falk, W. 1997. The interleukin-1 receptor complex and interleukin-1 signal transduction. European Cytokine Network 8(1), 5-17. 

---